Related Experiment Video
Updated: Apr 22, 2026
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
14.3K
Understanding and targeting the Rho kinase pathway in erectile dysfunction
Nikolai A Sopko1, Johanna L Hannan1, Trinity J Bivalacqua1
1James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, 1800 Orleans Street/Marburg 134, Baltimore, MD 21287, USA.
Nature Reviews. Urology
|October 15, 2014
Summary
Erectile dysfunction (ED) treatments may improve by targeting the RhoA-Rho-associated protein kinase (ROCK) pathway. Inhibiting RhoA-ROCK signaling offers a novel, nitric oxide-independent approach for treating ED.
Area of Science:
- Urology
- Molecular Biology
- Pharmacology
Background:
- Erectile dysfunction (ED) affects a significant portion of the male population and has multifactorial causes.
- Current ED therapies primarily focus on enhancing nitric oxide (NO) signaling pathways.
- Existing treatments are often ineffective for specific ED etiologies, such as diabetes, highlighting the need for novel therapeutic targets.
Purpose of the Study:
- To explore the role of RhoA-Rho-associated protein kinase (ROCK) signaling in penile physiology.
- To investigate the potential of RhoA-ROCK pathway inhibition as a therapeutic strategy for erectile dysfunction.
- To identify new molecular targets for ED treatment beyond NO-dependent mechanisms.
Main Methods:
- Review of existing research on penile erection mechanisms and RhoA-ROCK signaling.
- Analysis of the molecular pathways involved in smooth muscle relaxation and contraction in the penis.
- Evaluation of the potential of inhibiting RhoA-ROCK signaling for therapeutic benefit in ED.
Main Results:
- RhoA-ROCK signaling is crucial for maintaining penile flaccidity.
- Inhibition of RhoA-ROCK signaling promotes smooth muscle relaxation independently of nitric oxide.
- This NO-independent mechanism suggests a new avenue for ED treatment.
Conclusions:
- The RhoA-ROCK pathway represents a promising novel therapeutic target for erectile dysfunction.
- Targeting RhoA-ROCK offers a potential treatment modality for ED cases unresponsive to current therapies.
- Further research into RhoA-ROCK inhibitors could lead to advanced ED treatments.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
5.2K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
01:19Interactions Between Signaling Pathways
4.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
01:07MAPK Signaling Cascades
7.2K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.2K
01:22Amplifying Signals via Enzymatic Cascade
14.9K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
14.9K
01:25cAMP-dependent Protein Kinase Pathways
7.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.2K
01:20The JAK-STAT Signaling Pathway
10.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.0K